CSIMarket
 
Yubo International Biotech Limited  (MAGAA)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 120
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Yubo International Biotech Limited
Yubo International Biotech Limited is a biotechnology company that specializes in the development and production of medical devices and in vitro diagnostic (IVD) products. The company is based in China and has a strong focus on research and innovation in the field of biomedicine. They strive to improve the quality of healthcare by providing advanced and reliable diagnostic tools for diseases such as cancer, infectious diseases, and genetic disorders. Yubo International Biotech Limited works closely with medical professionals and institutions to ensure their products meet the highest standards of accuracy and efficiency.


   Company Address: Room 105 Xicheng District 0
   Company Phone Number: 0677-6010   Stock Exchange / Ticker: MAGAA
   MAGAA is expected to report next financial results on April 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Yubo International Biotech Limited

Yubo International Biotech Limited Generates Impressive Revenue Surge in Recent Fiscal Period 2.

Exciting Growth for Yubo International Biotech Limited in the Stock Market
The stock market is always full of surprises, and one company that has recently caught the attention of investors is Yubo International Biotech Limited. With the financial period closing in September 2023, the company has delivered some impressive results that are sure to please shareholders.
Let's start with the most important aspect - the company's financial performance. Yubo International Biotech Limited reached a zero gain of $0.00 per share, a figure that remained unchanged from the previous year. While this might not seem like much, it is important to note that the company has also seen a significant increase in revenue. Compared to the same reporting season a year ago, the company's revenue grew by a staggering 2839.026% to $0.43 million.

Yubo International Biotech Limited

Yubo International Biotech Limited Boasts Impressive Progress in Q2 2023 Despite Revenue Drop and Net Shortfall, Sparking Optimism for Future Success

Yubo International Biotech Limited, a prominent player in the Medical Equipment & Supplies sector, showcased remarkable progress in the financial second quarter of 2023. Despite challenges faced by the company, such as a drop in revenue and a net shortfall, there are numerous reasons to stay optimistic about its future prospects.
One of the most impressive aspects of Yubo International Biotech's performance is its achievement of break-even. In comparison to a year ago, where the company recorded a break-even per share, this marks a significant improvement. Furthermore, it surpassed the previous quarter's break-even per share of $0.00. This indicates that the company has successfully managed its costs and improved its financial position.

Yubo International Biotech Limited

Remarkable Financial Turnaround in Q1 2023 Sets Stage for Success

Yubo International Biotech Limited is a biotechnology company that specializes in research, development, and commercialization of innovative products for the healthcare industry. The company's focus is on developing cutting-edge medical technologies that have the potential to transform the treatment of various diseases and improve people's lives.
The recently announced financial results for the first quarter of 2023 reveal a significant improvement in the company's performance. Yubo International Biotech Limited has managed to reach break-even of $0.00 per share, which indicates that the company has achieved a balance between its revenue and expenses. This is a positive sign for the company, which had reported a deficit of $-0.579 million in the corresponding quarter a year ago.






 

Yubo International Biotech Limited's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com